KDR and liver cancer: While drugs that target VEGFR-2 have shown promise as a therapeutic approach for liver cancer, they also have some potential disadvantages, including, limited efficacy, adverse effects, off-target effects, development of resistance, cost and accessibility, and lack of long-term data.